Get the Stockscreener App
4.33
4.20%
-0.19
After Hours:
4.50
0.17
+3.93%
Anixa Biosciences Inc stock is traded at $4.33, with a volume of 289.56K.
It is down -4.20% in the last 24 hours and up +47.53% over the past month.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
See More
Previous Close:
$4.52
Open:
$4.48
24h Volume:
289.56K
Relative Volume:
1.89
Market Cap:
$142.53M
Revenue:
-
Net Income/Loss:
$-12.48M
P/E Ratio:
-11.10
EPS:
-0.39
Net Cash Flow:
$-7.93M
1W Performance:
+5.35%
1M Performance:
+47.53%
6M Performance:
+63.40%
1Y Performance:
+41.97%
1-Day Range:
$4.208
$4.4938
1-Week Range:
$4.00
$4.98
52-Week Range:
$2.07
$4.98
Anixa Biosciences Inc Stock (ANIX) Company Profile
Name
Anixa Biosciences Inc
Sector
Industry
Phone
408-708-9808
Address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
4.33 | 148.78M | 0 | -12.48M | -7.93M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | Maxim Group | Buy |
| Dec-23-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-12-21 | Initiated | H.C. Wainwright | Buy |
Anixa Biosciences Inc Stock (ANIX) Latest News
Is Anixa Biosciences Inc. building a consolidation baseWeekly Stock Recap & Stepwise Trade Signal Guides - newser.com
When is the best time to exit Anixa Biosciences Inc.Gap Down & Safe Entry Point Alerts - newser.com
Analyzing drawdowns of Anixa Biosciences Inc. with statistical toolsJuly 2025 Highlights & Reliable Entry Point Trade Alerts - newser.com
Developing predictive dashboards with Anixa Biosciences Inc. data2025 Risk Factors & Weekly Watchlist for Consistent Profits - newser.com
Will Anixa Biosciences Inc. stock benefit from AI adoptionJuly 2025 Rallies & Detailed Earnings Play Strategies - newser.com
Is Anixa Biosciences Inc. stock a buy for dividend growthMarket Trend Summary & Daily Stock Trend Reports - newser.com
Live market analysis of Anixa Biosciences Inc.Jobs Report & Growth Oriented Trading Recommendations - newser.com
Why global investors buy Anixa Biosciences Inc. (CY71) stockJuly 2025 Macro Moves & Capital Efficiency Focused Ideas - newser.com
Pattern recognition hints at Anixa Biosciences Inc. upsideJuly 2025 Selloffs & Real-Time Volume Analysis - newser.com
Is Anixa Biosciences Inc. (CY71) stock positioned for digital growth eraJuly 2025 Trade Ideas & Risk Adjusted Buy/Sell Alerts - newser.com
Candlestick signals on Anixa Biosciences Inc. stock todayQuarterly Growth Report & Daily Entry Point Alerts - newser.com
Is Anixa's First-In-Human Vaccine Poised For Regulatory Momentum? - RTTNews
Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial - The Malaysian Reserve
D. Boral Capital Maintains Anixa Biosciences (ANIX) Buy Recommendation - Nasdaq
D. Boral Capital Maintains 'Buy' Rating and $10 PT on ANIX | ANI - GuruFocus
D. Boral Capital Reaffirms "Buy" Rating for Anixa Biosciences (NASDAQ:ANIX) - MarketBeat
Anixa Biosciences (ANIX) Concludes Key Breast Cancer Vaccine Tri - GuruFocus
Anixa Biosciences announces completion of final patient visit in breast cancer vaccine clinical trial - MarketScreener
Is a relief rally coming for Anixa Biosciences Inc. holders2025 Volume Leaders & Safe Capital Growth Trade Ideas - newser.com
Anixa Biosciences Inc. stock trendline breakdownBuy Signal & Verified Short-Term Plans - newser.com
Can Anixa Biosciences Inc. (CY71) stock beat analyst consensusMarket Rally & High Yield Equity Trading Tips - newser.com
Will earnings trigger a reversal in Anixa Biosciences Inc.Weekly Volume Report & Risk Managed Investment Strategies - newser.com
How to use a screener to detect Anixa Biosciences Inc. breakoutsJuly 2025 Short Interest & Consistent Income Trade Recommendations - newser.com
How to manage a losing position in Anixa Biosciences Inc.Weekly Profit Recap & Free Long-Term Investment Growth Plans - newser.com
What analysts say about Anixa Biosciences Inc CY71 stockGeopolitical Risk Analysis & Minimal Risk High Reward - earlytimes.in
What drives Anixa Biosciences Inc stock priceRisk Mitigation Techniques & Build Wealth With Zero-Cost Tools - earlytimes.in
Anixa Biosciences Inc Stock (ANIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anixa Biosciences Inc Stock (ANIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KUMAR AMIT | Chief Executive Officer |
Jul 30 '25 |
Buy |
3.16 |
5,000 |
15,800 |
579,925 |
| Baskies Arnold M | Director |
Jul 18 '25 |
Buy |
3.39 |
5,000 |
16,950 |
125,000 |
| Titterton Lewis H jr | Director |
Jul 11 '25 |
Buy |
3.14 |
10,000 |
31,400 |
943,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 11 '25 |
Buy |
3.15 |
5,000 |
15,750 |
574,925 |
| KUMAR AMIT | Chief Executive Officer |
Jun 04 '25 |
Buy |
2.85 |
10,000 |
28,500 |
569,925 |
| Baskies Arnold M | Director |
Jan 28 '25 |
Buy |
2.82 |
5,000 |
14,100 |
120,000 |
| Titterton Lewis H jr | Director |
Jan 23 '25 |
Buy |
2.91 |
2,000 |
5,820 |
932,334 |
| Titterton Lewis H jr | Director |
Jan 24 '25 |
Buy |
3.00 |
1,000 |
3,000 |
933,334 |
| Titterton Lewis H jr | Director |
Jan 22 '25 |
Buy |
3.01 |
2,000 |
6,020 |
930,334 |
| Titterton Lewis H jr | Director |
Jan 21 '25 |
Buy |
2.59 |
6,000 |
15,540 |
928,334 |
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):